Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
March 19 2020 - 8:30AM
Celsion Corporation (NASDAQ: CLSN) announced today that the Company
will host a conference call to discuss financial results for the
year ended December 31, 2019 and provide an update on its
development programs for ThermoDox®, its proprietary heat-activated
liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA
plasmid vector formulated into a nanoparticle with a non-viral
delivery system at 11:00 a.m. EDT on Thursday, March 26, 2020.
To participate in the call, interested parties
may dial 1-800-367-2403 (Toll-Free/North America) or 1-334-777-6978
(International/Toll) and ask for the Celsion Corporation Fourth
Quarter and Year-End 2019 Earnings Call (Conference Code: 8257530)
to register ten minutes before the call is scheduled to begin. The
call will also be broadcast live on the internet at
www.celsion.com. The call will be archived for replay on Friday,
March 27, 2020 and will remain available until April 10, 2020. The
replay can be accessed at 1-719-457-0820 or 1-888-203-1112 using
Conference ID: 8257530. An audio replay of the call will also be
available on the Company's website, www.celsion.com, for 90 days
after 2:00 p.m. EDT Thursday, March 26, 2020.
About Celsion Corporation
Celsion is a fully integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in development for other cancer indications. The
Company’s product pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian cancer.
Celsion has two platform technologies for the development of novel
nucleic acid-based immunotherapies and other anti-cancer DNA or RNA
therapies. For more information on Celsion, visit:
http://www.celsion.com. (CLSN-FIN).
Celsion wishes to inform readers that
forward-looking statements in this release are made pursuant to the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data; the
significant expense, time, and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its future
development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in Celsion's periodic reports and
prospectuses filed with the Securities and Exchange Commission.
Celsion assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Celsion
Investor Contact |
LHA
Investor Relations |
Jeffrey W.
Church |
Kim Sutton
Golodetz |
Executive Vice
President & CFO |
212-838-3777 |
609-482-2455 |
kgolodetz@lhai.com |
jchurch@celsion.com |
|
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024